Screener
Corcept Therapeutics CORT Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Total assets | $888,702 | $836,651 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $14,910 | $40,444 |
| Accrued research and development expenses | 21,628 | 33,954 |
| Accrued and other liabilities | 115,347 | 90,603 |
| Short-term operating lease liability | 1,917 | 1,084 |
| Total current liabilities | 153,802 | 166,085 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Corcept Therapeutics's accounts payable?
- Corcept Therapeutics (CORT) reported accounts payable of $14.91M in Q2 2026.
- How has Corcept Therapeutics's accounts payable changed year-over-year?
- Corcept Therapeutics's accounts payable decreased by 36.6% year-over-year, from $23.53M to $14.91M.
- What is the long-term trend for Corcept Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), Corcept Therapeutics's accounts payable has grown at a 30.8% compound annual growth rate (CAGR), from $10.55M to $40.44M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Corcept Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude